- Tetra Bio-Pharma Inc. (TBP) has signed an agreement to co-develop ARDS-003 in combination with Favipiravir
- ARDS-003 is a cannabis-derived drug helping control acute systemic inflammation
- Favipiravir is an antiviral drug that treats 12 families of viruses, including COVID-19
- Based on previous data, a combination product of Favipiravir and ARDS-003 may be able to prevent certain consequences of COVID-19
- Tetra Bio-Pharma Inc. (TBP) is unchanged trading at $0.06 per share as of 11:40 a.m. ET
Tetra Bio-Pharma (TBP) has signed an agreement with Cellvera Global Holdings LLC to co-develop a new product using ARDS-003 in combination with Favipiravir.
Tetra Bio-Pharma, a cannabis-derived drug developer, stated that ARDS-003 is a novel cannabis-derived drug product which may be able to control acute systemic inflammation and prevent sepsis, acute respiratory distress syndrome, and organ damage. Favipiravir is an antiviral drug which works against 12 families of viruses, including coronaviruses Ebola, Zika, dengue, rabies, and more.
“This partnership with a pharmaceutical company with global reach is a sign of the potential for the ARDS-003 drug asset… working jointly with Cellvera to bring this combination drug product forward to improve treatment options for patients worldwide,” Guy Chamberland, CEO and CRO of Tetra Bio-Pharma, said.
Cellvera owns the rights to Favipiravir, which has a long and verified history of safety and efficacy and was initially developed to treat pandemic influenza. The drug targets the protein needed for the coronavirus to replicate and then ensures the virus cannot copy itself.
The companies believe, based on data from a drug discovery platform, that a combination product of Favipiravir and ARDS-003 may be able to prevent certain consequences of COVID-19, such as severe pulmonary inflammation.
“The ongoing complexities of COVID-19 require multiple treatment options… we hope to offer this additional treatment option to patients,” Mary O’Brien, CEO of Cellvera, said.
Tetra Bio-Pharma Inc. (TBP) is unchanged trading at $0.06 per share as of 11:40 a.m. ET.